Elderly grandparents caring for young grandchildren face respiratory virus risks as respiratory syncytial virus circulates alongside early-arriving influenza, according to a report. Addressing these overlapping risks requires looking beyond standard seasonal immunizations, as a study of 14,819,226 people aged 65 and older by a U.S. Food and Drug Administration research team showed that RSV vaccine recipients experienced an 85% reduction in virus-related deaths and an 82% drop in hospitalizations compared to unvaccinated individuals.
Among roughly 3 million vaccinated individuals in the research group, fewer than 20 people—or less than 0.0006%—were hospitalized and died from the virus. The single shot costs between 250,000 and 300,000 won and is not included in national free inoculation programs, yet it has earned the nickname 효도 백신
(filial piety vaccine) among doctors as adult children frequently bring their parents to receive it.
Grandchild Contact and Rising Influenza Pressures
In Korean culture, close contact between grandchildren and grandparents is common, with many working parents relying on older relatives for childcare. While young children often recover quickly from mild colds, the transmission of respiratory syncytial virus to older adults with weaker hearts or lungs can lead to severe complications.
꼬마들이 뛰어놀다 할머니, 할아버지를 껴안고 그러면서 RSV를 옮긴다
Compounding these risks, influenza has arrived earlier than usual. The Korea Disease Control and Prevention Agency issued an influenza advisory on September 11, more than a month earlier than the previous year’s October 17 advisory. During the first week of September, suspected outpatient flu cases reached 25.3 per 1,000 patients, nearly four times the 6.6 cases recorded during the same period a year earlier.
Comparative Vaccine Effectiveness and Ongoing Trials
The 2023–2024 winter data evaluated in a September international journal JAMA Network Open study estimated that RSV-related hospitalizations fell by 81.8% among vaccinated persons, with effectiveness remaining notably steady even for those over 85 years old.
Other immunizations also demonstrated measurable protection for older demographics. A September JAMA review indicated that previous winter COVID-19 vaccines reduced virus-related hospitalizations by 53% among adults aged 65 and older, following an earlier winter season where severe outcomes requiring ventilators or resulting in hospital deaths dropped by 73%. Meanwhile, domestic COVID-19 hospitalizations remain concentrated among older populations, with 63%—or 6 in 10 patients—aged 65 or older. Traditional influenza vaccines lowered flu-related mortality in older adults by 29% to 65.8% depending on the study.
With seasonal strategies requiring a balance between free national inoculations and out-of-pocket options for RSV, COVID-19, and pneumococcal disease, individuals must weigh their age and underlying health conditions when planning winter vaccinations. Further details on customized vaccination strategies are available through the JoongAng Ilbo report.
